153 related articles for article (PubMed ID: 3718544)
1. Selective sensitivity to tiazofurin of human leukemic cells.
Jayaram HN; Pillwein K; Nichols CR; Hoffman R; Weber G
Biochem Pharmacol; 1986 Jun; 35(12):2029-32. PubMed ID: 3718544
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
[TBL] [Abstract][Full Text] [Related]
3. Determination of thiazole-4-carboxamide adenine dinucleotide (TAD) levels in mononuclear cells of leukemic patients treated with tiazofurin.
Zhen W; Jayaram HN; Weber G
Biochem Pharmacol; 1991 Jan; 41(2):281-6. PubMed ID: 1989637
[TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
[TBL] [Abstract][Full Text] [Related]
6. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
Tricot GJ; Jayaram HN; Nichols CR; Pennington K; Lapis E; Weber G; Hoffman R
Cancer Res; 1987 Sep; 47(18):4988-91. PubMed ID: 3476200
[TBL] [Abstract][Full Text] [Related]
7. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro.
Roberts JD; Tong WP; Hartshorn JN; Hacker MP
Cancer Lett; 1986 Aug; 32(2):193-7. PubMed ID: 3756845
[TBL] [Abstract][Full Text] [Related]
9. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
10. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of resistance to tiazofurin in hepatoma 3924A.
Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
[TBL] [Abstract][Full Text] [Related]
12. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of tiazofurin in human colon carcinoma HT-29.
Zhen W; Jayaram HN; Weber G
Cancer Invest; 1992; 10(6):505-11. PubMed ID: 1358409
[TBL] [Abstract][Full Text] [Related]
14. Tiazofurin action in leukemia: evidence for down-regulation of oncogenes and synergism with retinoic acid.
Weber G; Yamaji Y; Nagai M; Natsumeda Y; Jayaram HN; Zhen WN; Paulik E
Adv Enzyme Regul; 1990; 30():35-45. PubMed ID: 2206022
[TBL] [Abstract][Full Text] [Related]
15. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
[TBL] [Abstract][Full Text] [Related]
16. Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.
Pillwein K; Jayaram HN; Weber G
Blut; 1988 Aug; 57(2):97-100. PubMed ID: 3165681
[TBL] [Abstract][Full Text] [Related]
17. Biochemical mechanisms of resistance to tiazofurin.
Jayaram HN
Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
[TBL] [Abstract][Full Text] [Related]
18. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
20. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
